Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA (adenine(37)-N6)-methyltransferase (TRMO) is an enzyme responsible for the methylation of adenine at the N6 position at the 37th nucleotide of certain tRNAs, a modification critical for the maintenance of correct codon–anticodon pairing and translational fidelity during protein synthesis. Like other tRNA methyltransferases, TRMO is a member of the class I methyltransferase family, characterized by the Rossmann-like fold. Its activity ensures proper tRNA structure and function, preventing translational errors. Aberrant function or misregulation of tRNA-modifying enzymes, including TRMO, has been linked to human diseases such as cancer and metabolic impairment through the disruption of normal translational fidelity and protein homeostasis[1][2][4]. TRMO shares sequence and structural features with other methyltransferases and is essential for normal cellular biosynthetic processes.
Catalyzes N6-methylation of adenine(37) in tRNA, facilitating proper decoding and translation; may regulate the stability and function of tRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA (adenine(37)-N6)-methyltransferase (TRMO).